{
  "ticker": "SGMO",
  "company_name": "Sangamo Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03041324",
      "title": "Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Mucopolysaccharidosis II, MPS II",
      "start_date": "2017-05-11",
      "completion_date": "2021-05-07",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    },
    {
      "nct_id": "NCT02500849",
      "title": "Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "HIV",
      "start_date": "2016-03-10",
      "completion_date": "2026-08-24",
      "enrollment": 0,
      "sponsor": "City of Hope Medical Center"
    },
    {
      "nct_id": "NCT00087789",
      "title": "CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Alzheimer's Disease",
      "start_date": "2004-06",
      "completion_date": "2010-05",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    },
    {
      "nct_id": "NCT00476931",
      "title": "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy",
      "start_date": "2007-05",
      "completion_date": "2010-12",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    },
    {
      "nct_id": "NCT00252850",
      "title": "Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Parkinson's Disease",
      "start_date": "2005-06",
      "completion_date": "2007-03",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    },
    {
      "nct_id": "NCT02225665",
      "title": "Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Human Immunodeficiency Virus (HIV)",
      "start_date": "2014-08",
      "completion_date": "2018-06",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    },
    {
      "nct_id": "NCT04817774",
      "title": "Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Kidney Transplant Rejection, End Stage Renal Disease",
      "start_date": "2021-03-17",
      "completion_date": "2025-10-29",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    },
    {
      "nct_id": "NCT00985517",
      "title": "Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Idiopathic Parkinson's Disease",
      "start_date": "2009-10-29",
      "completion_date": "2017-11-16",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    },
    {
      "nct_id": "NCT05145062",
      "title": "Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "",
      "condition": "Blood and Lymphatic Diseases",
      "start_date": "2021-12-21",
      "completion_date": "2038-07-14",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    },
    {
      "nct_id": "NCT00406458",
      "title": "Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy",
      "start_date": "2006-11",
      "completion_date": "2009-05",
      "enrollment": 0,
      "sponsor": "Sangamo Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 30,
    "by_phase": {
      "PHASE1, PHASE2": 11,
      "PHASE1": 7,
      "PHASE2": 7,
      "": 5
    },
    "by_status": {
      "TERMINATED": 4,
      "ACTIVE_NOT_RECRUITING": 5,
      "COMPLETED": 19,
      "RECRUITING": 1,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 7,
    "completed_trials": 19,
    "conditions": [
      "Alzheimer's Disease",
      "Amyotrophic Lateral Sclerosis",
      "Blood and Lymphatic Diseases",
      "Chronic Neuropathic Pain",
      "Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy",
      "Diabetic Neuropathy",
      "Fabry Disease",
      "Fabry Disease, Fabry Disease, Cardiac Variant",
      "HIV",
      "HIV Infection, HIV Infections",
      "HIV, HIV Infection",
      "HIV, HIV Infections",
      "HIV-1-infection",
      "Hemophilia B",
      "Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II",
      "Human Immunodeficiency Virus (HIV)",
      "Idiopathic Parkinson's Disease",
      "Kidney Transplant Rejection, End Stage Renal Disease",
      "MPS I",
      "Mucopolysaccharidosis II, MPS II",
      "Parkinson's Disease",
      "Sickle Cell Disease",
      "Transfusion Dependent Beta-thalassemia"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:47.677807",
    "search_query": "Sangamo Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Sangamo+Therapeutics,+Inc."
  }
}